by Richard Boyd and Aleta Pupovac
A question which has long baffled scientists, frustrated clinicians and devastated patients is why does the immune system so effectively defend against infections but so poorly deal with cancer? What lessons can be learnt?
Thanks to a molecular biology-led revolution in immunotherapy, we are now beginning to strategically apply the immune […]
Heather Hawkins, Cartherics Board Advisor and patient advocate, shares her personal journey with ovarian cancer in the hope that it will help raise awareness of the importance of early diagnosis.
My ovarian cancer journey began in December 2006.
At the time I was a 41-year-old busy working mother of two, running a film and video production company […]
Commercialising science and technology is key to the continued growth of Australia’s vibrant life sciences industry. Translating research into real-world results has important implications for consumers and businesses alike.
Bio Connections Australia 2023 was held today at Crown Promenade Melbourne with an important focus on translation, drug development and expediting Australia’s science into commercialisation.
The forum […]
The 2023 Australia-China Science and Innovation Forum focused on leading-edge Australian and Chinese biomedical research collaborations and commercialisation. The forum was held at Monash University’s Suzhou campus in China last week and was also available for online attendance.
The forum’s program was designed to promote connections and enhance collaborations between the Australian and Chinese research and […]
Cartherics’ Director of IP & Licensing, Telma Mantas recently attended the ACI’s 21st Advanced Summit on Life Sciences Patents in New York City. The summit provided the opportunity to engage in face-to-face discussions with leading stakeholders on the best practices to enhance global protections for patent portfolios. Now more than ever in these increasingly […]
Melbourne, Australia, 24 May 2023 – Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it is presenting at the upcoming 2023 BIO International Convention June 5-8, 2023, in Boston, Massachusetts. CEO Prof. Alan Trounson will meet with senior biotech executives, business development leaders […]
Cartherics is delighted to announce that Rasa Islam has successfully completed her PhD candidature.
Rasa’s research thesis, titled, Re-engineering the function of natural killer cell receptors via CRISPR/Cas9: a new approach for ‘off the shelf’ immunotherapy, investigated the generation of Natural Killer (NK) cells (immune cells) from gene-edited stem cells to provide an ‘off-the-shelf’ supply for […]
Cartherics is pleased to announce that PhD Candidate, Van To, will be presenting at the Association for Cancer Immunotherapy’s 20th CIMT Annual Meeting in Germany.
CIMT is Europe’s largest meeting focused on cancer immunotherapy research and development. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As […]
Melbourne, Australia, 28 April 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has granted Shunxi Holding Group Co Ltd (“Shunxi”) a licence to develop, manufacture and commercialise Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumours including […]
Cartherics will be presenting at the ThymOZ 2023 International Conference on T Cells to be held from 22 -26 March at Heron Island in Queensland, Australia. The conference covers a broad range of topics including T cell differentiation and function, stromal cell biology, immunotherapy and tissue regeneration.
Rachelle Duffin, PhD Candidate at Cartherics will be presenting […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
